June 9, 2014

“The lack of high-quality controlled human studies precludes ILE as a first-line agent for indications other than local anesthetic systemic toxicity”

Thanks to James Cao, MD for this excellent review of the literature on the use of ILE therapy in various toxicologic emergencies.

We’re grateful to Mathew Miskimon, MD PhD for providing this morbidity and mortality (and improvement!) case from Janus General. Includes a nice discussion at the end on the systemic factors contributing to the outcome.